Anti-tumor activity of SM1052, a novel artemisinin derivative, in the human endometrial carcinoma RL95-2 cells
文献类型：期刊论文
| 作者 | Zhou Jieyun2; Xie Shuwu2; Zhang Yu1; Li Guoting2; Gui Youlun2; Li Ying1; Zhu Yan2 |
| 刊名 | Chinese Journal New Drugs
 |
| 出版日期 | 2014 |
| 卷号 | 23期号:12页码:1431-1437 |
| 关键词 | artemisinin dimer derivative antitumor cell cycle apoptosis |
| ISSN号 | 1003-3734 |
| 其他题名 | 新型青蒿素衍生物SM1052抗人子宫内膜癌RL95-2肿瘤活性研究 |
| 文献子类 | Article |
| 英文摘要 | Objective: To evaluate the antitumor activity of SM1052, a novel artemisinin derivatives, in the human endometrial carcinoma RL95-2 cells in vitro and in vivo and to investigate the mechanism of action. Methods: Cytotoxic activity of SM1052 in vitro was evaluated by CCK-8 assay in RL95-2 cells. In vivo antitumor activity was tested in nude mice with xenograft of the cancer cells. Cell cycle was determined by flow cytometry, the rate of early apoptosis was measured by flow cytometry using AnnexinⅤ-FITC/PI double staining, and the expression of Bcl-2 and Bax proteins was detected by Western blotting. Results: SM1052 significantly inhibited the proliferation of RL95-2 cells, and cell viability was (13.830.43)% at 50 mumol·L~(-1) of SM1052. SM1052 (10 mg·kg~(-1)) remarkably inhibited growth of RL95-2 xenograft tumor. SM1052 (50 mumol·L~(-1)) significantly induced cell cycle arrest in G_2/M and early apoptosis, increased Bax expression and down-regulated Bcl-2 expression. Conclusion: SM1052 has effective antitumor activity in the human endometrial carcinoma RL95-2 cells in vitro and in vivo. The mechanisms of action may involve induction of cell cycle arrest and regulation of the expression of apoptosis-related proteins (Bcl-2 and Bax). |
| 资助项目 | 上海中医药大学开放基金[00000000] |
| WOS研究方向 | Pharmacology & Pharmacy (provided by Clarivate Analytics) |
| 语种 | 中文 |
| CSCD记录号 | CSCD:5172348 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/269335]  |
| 专题 | 药物化学研究室 |
| 作者单位 | 1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. 2.Shanghai Institute of Planned Parenthood Research, NPFPC Laboratory of Contraception and Devices, Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Devices, Shanghai 200032, China.; |
| 推荐引用方式 GB/T 7714 | Zhou Jieyun,Xie Shuwu,Zhang Yu,et al. Anti-tumor activity of SM1052, a novel artemisinin derivative, in the human endometrial carcinoma RL95-2 cells[J]. Chinese Journal New Drugs,2014,23(12):1431-1437. |
| APA | Zhou Jieyun.,Xie Shuwu.,Zhang Yu.,Li Guoting.,Gui Youlun.,...&Zhu Yan.(2014).Anti-tumor activity of SM1052, a novel artemisinin derivative, in the human endometrial carcinoma RL95-2 cells.Chinese Journal New Drugs,23(12),1431-1437. |
| MLA | Zhou Jieyun,et al."Anti-tumor activity of SM1052, a novel artemisinin derivative, in the human endometrial carcinoma RL95-2 cells".Chinese Journal New Drugs 23.12(2014):1431-1437. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。